In vitro mineralization by preosteoblasts in poly(DL-lactide-co-glycolide) inverse opal scaffolds reinforced with hydroxyapatite nanoparticles.
Inverse opal scaffolds made of poly(DL-lactide-co-glycolide) (PLGA) and hydroxyapatite (HAp) were fabricated using cubic-closed-packed (ccp) lattices of uniform gelatin microspheres as templates and evaluated for bone tissue engineering. The scaffolds exhibited a uniform pore size (213 +/- 4.4 microm), a porosity of approximately 75%, and an excellent connectivity in three dimensions. Three different formulations were examined: pure PLGA, HAp-impregnated PLGA (PLGA/HAp), and apatite (Ap)-coated PLGA/HAp. After seeding with preosteoblasts (MC3T3-E1), the samples were cultured for different periods of time and then characterized by X-ray microcomputed tomography (micro-CT) and scanning electron microscopy to evaluate osteoinductivity in terms of the amount and spatial distribution of mineral secreted from the differentiated preosteoblasts. Our results indicate that preosteoblasts cultured in the Ap-coated PLGA/HAp scaffolds secreted the largest amount of mineral, which was also homogeneously distributed throughout the scaffolds. In contrast, the cells in the pure PLGA scaffolds secreted very little mineral, which was mainly deposited around the perimeter of the scaffolds. These results suggest that the uniform pore structure and favorable surface properties could facilitate the uniform secretion of extracellular matrix from cells throughout the scaffold. The Ap-coated PLGA/HAp scaffold with uniform pore structure could be a promising material for bone tissue engineering.
Choi
Sung-Wook
SW
Department of Biomedical Engineering, Washington University, St. Louis, Missouri 63130, USA.
Zhang
Yu
Y
Thomopoulos
Stavros
S
Xia
Younan
Y
D000818:Animals; D001842:Bone and Bones / Q000166:cytology; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D017886:Durapatite / Q000737:chemistry*; D051379:Mice; D008903:Minerals / Q000378:metabolism*; D053758:Nanoparticles / Q000737:chemistry*; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D011098:Polyglactin 910 / Q000737:chemistry* / Q000494:pharmacology*; D023822:Tissue Engineering; D054457:Tissue Scaffolds / Q000737:chemistry*; D055114:X-Ray Microtomography
D008903:Minerals; D011098:Polyglactin 910; D017886:Durapatite
J Biomed Mater Res. 2002 Mar 15;59(4):709-15
11774333
J Biomed Mater Res A. 2004 Feb 1;68(2):227-34
14704964
Biomaterials. 2000 Sep;21(17):1803-10
10905463
Clin Orthop Relat Res. 2002 Feb;(395):81-98
11937868
Biomaterials. 2005 Sep;26(25):5221-30
15792549
Adv Mater. 2009 Apr 15;21(29):2997-3001
19710950
Biomaterials. 2001 Jun;22(11):1279-88
11336300
Langmuir. 2008 Dec 16;24(24):14145-50
19053657
J Bone Miner Res. 1995 Jan;10(1):157-63
7747623
Biomaterials. 2007 Feb;28(6):1152-62
17092555
Small. 2009 Apr;5(4):454-9
19189332
J Biomed Mater Res. 1996 Sep;32(1):55-63
8864873
Biomaterials. 2005 Mar;26(8):899-904
15353201
Biomaterials. 2005 Mar;26(7):779-85
15350783
Biomaterials. 1999 Oct;20(19):1799-806
10509190
Nature. 1996 Aug 1;382(6590):448-52
8684484
J Biomed Mater Res A. 2003 Dec 15;67(4):1196-204
14624506
Biomaterials. 2004 Aug;25(19):4749-57
15120521
Biomaterials. 2001 Jun;22(12):1467-74
11374445
Biomaterials. 2005 Jan;26(3):285-95
15262470
Biomaterials. 2006 Oct;27(28):4894-903
16762408
Biomaterials. 2009 Jun;30(16):2967-74
19286251